These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 34707513)

  • 21. Projected clinical benefits of dapagliflozin in patients with heart failure with preserved ejection fraction.
    Montero-Pérez-Barquero M; Escobar-Cervantes C; Llàcer P; Quirós-López R; Trullás JC; Cerqueiro JM; Epelde-Gonzálo F; Carrera-Izquierdo M; Formiga F; González-Franco A; Casado-Cerrada J
    Future Cardiol; 2023 May; 19(6):333-342. PubMed ID: 37382199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome.
    Oliva F; Mortara A; Cacciatore G; Chinaglia A; Di Lenarda A; Gorini M; Metra M; Senni M; Maggioni AP; Tavazzi L;
    Eur J Heart Fail; 2012 Nov; 14(11):1208-17. PubMed ID: 22833614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammation in heart failure: pathophysiology and therapeutic strategies.
    Boulet J; Sridhar VS; Bouabdallaoui N; Tardif JC; White M
    Inflamm Res; 2024 May; 73(5):709-723. PubMed ID: 38546848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The usefulness of C-reactive protein for the prediction of post-infarct left ventricular systolic dysfunction and heart failure.
    Swiatkiewicz I; Taub PR
    Kardiol Pol; 2018; 76(5):821-829. PubMed ID: 29633232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation in chronic heart failure.
    Parish RC; Evans JD
    Ann Pharmacother; 2008 Jul; 42(7):1002-16. PubMed ID: 18477736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New drugs in preclinical and early stage clinical development in the treatment of heart failure.
    Tamargo J; Caballero R; Delpón E
    Expert Opin Investig Drugs; 2019 Jan; 28(1):51-71. PubMed ID: 30523722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory pathways in patients with heart failure and preserved ejection fraction.
    Niethammer M; Sieber M; von Haehling S; Anker SD; Munzel T; Horstick G; Genth-Zotz S
    Int J Cardiol; 2008 Sep; 129(1):111-7. PubMed ID: 17658631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of EP4 receptor limits transition of acute to chronic heart failure in lipoxygenase deficient mice.
    Kain V; Ingle KA; Rajasekaran NS; Halade GV
    Theranostics; 2021; 11(6):2742-2754. PubMed ID: 33456570
    [No Abstract]   [Full Text] [Related]  

  • 29. Inflammation in acute heart failure.
    Garofalo M; Corso R; Tomasoni D; Adamo M; Lombardi CM; Inciardi RM; Gussago C; Di Mario C; Metra M; Pagnesi M
    Front Cardiovasc Med; 2023; 10():1235178. PubMed ID: 38045909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting BNIP3 in inflammation-mediated heart failure: a novel concept in heart failure therapy.
    Fordjour PA; Wang L; Gao H; Li L; Wang Y; Nyagblordzro M; Agyemang K; Fan G
    Heart Fail Rev; 2016 Sep; 21(5):489-97. PubMed ID: 27112557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.
    Nieminen MS; Brutsaert D; Dickstein K; Drexler H; Follath F; Harjola VP; Hochadel M; Komajda M; Lassus J; Lopez-Sendon JL; Ponikowski P; Tavazzi L; ;
    Eur Heart J; 2006 Nov; 27(22):2725-36. PubMed ID: 17000631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
    Shah RV; Desai AS; Givertz MM
    J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited.
    Paulus WJ; Zile MR
    Circ Res; 2021 May; 128(10):1451-1467. PubMed ID: 33983831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inducible NO synthase is constitutively expressed in porcine myocardium and its level decreases along with tachycardia-induced heart failure.
    Paslawska U; Kiczak L; Bania J; Paslawski R; Janiszewski A; Dzięgiel P; Zacharski M; Tomaszek A; Michlik K
    Cardiovasc Pathol; 2016; 25(1):3-11. PubMed ID: 26361649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry.
    Bhatt AS; Berg DD; Bohula EA; Alviar CL; Baird-Zars VM; Barnett CF; Burke JA; Carnicelli AP; Chaudhry SP; Daniels LB; Fang JC; Fordyce CB; Gerber DA; Guo J; Jentzer JC; Katz JN; Keller N; Kontos MC; Lawler PR; Menon V; Metkus TS; Nativi-Nicolau J; Phreaner N; Roswell RO; Sinha SS; Jeffrey Snell R; Solomon MA; Van Diepen S; Morrow DA
    J Card Fail; 2021 Oct; 27(10):1073-1081. PubMed ID: 34625127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinctive patterns of inflammation across the heart failure syndrome.
    Schiattarella GG; Sequeira V; Ameri P
    Heart Fail Rev; 2021 Nov; 26(6):1333-1344. PubMed ID: 32219614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
    DE Vecchis R; Ariano C
    Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of interleukins in heart failure with reduced ejection fraction.
    Segiet OA; Piecuch A; Mielanczyk L; Michalski M; Nowalany-Kozielska E
    Anatol J Cardiol; 2019 Nov; 22(6):287-299. PubMed ID: 31789611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
    Drugs Context; 2023; 12():. PubMed ID: 36660013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.